- The clinical efficacy and safety of naftopidil 75 mg on benign prostatic hyperplasia patients with moderate or severe urinary disturbance - (https://pubmed.ncbi.nlm.nih.gov/19462821/ )
- Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia - (https://pubmed.ncbi.nlm.nih.gov/30306544/ )
- Safety profile of medication used during pregnancy: results of a multinational European study - (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518438/ )
- Outcomes and complications of naftopidil versus tamsulosin for elderly men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review and meta-analysis - (https://pubmed.ncbi.nlm.nih.gov/34189764/ )
Naftopidil (Nafodil (50mg)) is prescribed in Japan for the treatment of benign prostatic hyperplasia (BPH) and benign prostatic obstruction, associated with lower urinary tract symptoms (LUTS), hypertension, cardiac valve disease, and distal ureteral stones.
Further large-scale, randomized, placebo-controlled studies need to be done to see if the Naftopidil (Nafodil (50mg)) efficacy and safety data that is applicable to Japanese can be extended to white, black and Hispanic men having LUTS/BPH in western countries.
The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak with a healthcare professional.
Nafodil (50mg) - Intas Pharmaceutical Ltd.
Nafodil (50mg) Tablet
Generic : Naftopidil
Substitute/Alternative Medication to Nafodil (50mg)
When is Nafodil (50mg) prescribed?
It is prescribed for -